论文信息 - Gestational trophoblastic neoplasia: one size does not fit all - Authors' reply. - 字舞流文

Gestational trophoblastic neoplasia: one size does not fit all - Authors' reply.

R. Berkowitz | M. Seckl | A. Braga

[1] R. Berkowitz,et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. , 2021, The Lancet. Oncology.

[2] R. Berkowitz,et al. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? , 2019, Gynecologic oncology.

[3] M. Seckl,et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide , 2019, World journal of clinical oncology.

[4] R. Coleman,et al. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. , 2016, Gynecologic oncology.

[5] N. Sebire,et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 , 2012, British Journal of Cancer.